Suchergebnisse - "Kaufman, Howard L"

PubPharm (461)

1

Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

enthalten in: Journal for immunotherapy of cancer | 2024

von Bommareddy, P. | Wakimoto, H. | Martuza, R. | +3

2

Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment

enthalten in: JCI insight | 2023

von Battula, S. | Papastoitsis, G. | Kaufman, H. | +2

3

Attenuated Dengue Virus PV001-DV Induces Oncolytic Tumor Cell Death and Potent Immune Responses

enthalten in: ResearchSquare.com | 2023

von Goldufsky, J. | Daniels, P. | Williams, M. | +7

4

Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy

enthalten in: Human gene therapy | 2023

von Wang, H. | Borlongan, M. | Hemminki, A. | +5

5

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer

enthalten in: Journal for immunotherapy of cancer | 2023

von Jhawar, S. | Wang, S. | Thandoni, A. | +19

ErratumIn: J Immunother Cancer. 2024 Jan 31;12(1):. - PMID 38296599

6

Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses

enthalten in: Journal of translational medicine | 2023

von Goldufsky, J. | Daniels, P. | Williams, M. | +7

7

Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses

enthalten in: Journal of translational medicine | 2023

von Goldufsky, J. | Daniels, P. | Williams, M. | +7

8

Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses

enthalten in: Journal of translational medicine | 2023

von Goldufsky, J. | Daniels, P. | Williams, M. | +7

9

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma : results from the CAPRA study

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Silk, A. | O'Day, S. | Kaufman, H. | +19

10

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors : A multi-hospital cohort study

enthalten in: Journal of the American Academy of Dermatology | 2023

von Leung, B. | Wan, G. | Nguyen, N. | +11

CommentIn: J Am Acad Dermatol. 2023 Jun;88(6):1260. - PMID 36967021

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[47]